Becton Dickinson management check

BDX · Health Care · Health Care Equipment · CEO Thomas E. Polen

Filings as of

58
Management score, ranked 353rd of 487 · 42nd of 60 in Health Care2 good · 4 to watch · 1 flaggedStrongest: clean books · Weakest: owner returns · Best and worst run in Health Care →

The seven checks

  • Flag

    Have owners done well?

    Trailed its chosen peersOwners$89Peers$130

    What $100 became since fiscal 2021

    1124th
    Detail

    $100 invested at the start of fiscal 2021 grew to $89, against $130 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20212025

    Pay actually paid $100 value, each on its own scale

    8965th
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.78 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Watch

    What does the CEO cost owners?

    1.0% of net income

    $17.1m pay · $1.7bn net income, FY2025

    0.1%1%3%10%
    4950th
    Detail

    $17.1m of reported pay in fiscal 2025, against $1.7bn of net income.

  • Watch

    Do they own the stock?

    CEO stake ≈ 1.6 years of pay

    130,402 shares ≈ $27.4m

    0.1y1y5y20y100y

    6 mo: ▲ $0 bought · ▼ $2.7m sold

    4549th
    Detail

    The CEO holds 130,402 shares, directly or through trusts (unvested awards not counted): about 1.6 years of pay. Light activity: no buys, $2.7m sold in six months. 11 of 12 sales ran on pre-arranged 10b5-1 plans.

  • Watch

    Are owners being diluted?

    Share count growing2021 · 292m2025 · 289m

    Diluted shares +0.0% a year; flagged above +2%

    0%10%20%

    Stock pay 1.2% of revenue

    5034th
    Detail

    Diluted shares changed +0.0% a year over the last three fiscal years. Stock-based pay was 1.2% of revenue in the latest year.

  • Watch

    Is leadership stable?

    13 leadership filings in 3 years

    13 filings under 8-K 5.02 in 3 years

    0101420+

    CEO: Thomas E. Polen

    6038th
    Detail

    CEO in the pay table: Thomas E. Polen. 13 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed December 18, 2025.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
$0$14.9m$29.8m$10020212022202320242025$89$130

Pay tied most to Revenue

Other key measuresRevenue*Adjusted EPS*Free cash flow*Operating margin*ROIC*

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Thomas E. Polen$17.1m$3.5m$4.3m$89$130$1.7bn
2024—$17.3m$9.5m$4.0m$113$127$1.7bn
2023—$17.3m$29.8m$4.5m$119$102$1.5bn
2022—$16.7m$15.0m$4.2m$101$90$1.8bn
2021—$14.2m$16.7m$3.7m$107$127$2.1bn

Insiders and the CEO's stakeQuiet

Chairman, CEO and President
Thomas E Jr Polen
Shares held
130,402
At that filing's price
≈ $27.4m
Latest Form 4
Nov 5, 2026

Light activity: no buys, $2.7m sold in six months. 11 of 12 sales ran on pre-arranged 10b5-1 plans.

Open-market trades by officers and directors since May 21, 2026.

  • SoldThomas E Jr PolenChairman, CEO and President · 10b5-1 plan$1.8mNov 5, 2026
  • SoldRoland GoetteEVP and President, EMEA$441kAug 11, 2026
  • SoldMichael David GarrisonEVP & Pres Med.Essntl&BioPharm · 10b5-1 plan$327kJun 24, 2026
  • SoldMichael FeldEVP, Chief Revenue Officer · 10b5-1 plan$94kOct 26, 2026

Leadership and governance on file

20222023202420252026Leadership 20Votes 5
All 20 filings

Latest shareholder vote results: Jan 30, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $9.3bn returned to owners in buybacks and dividends, 106% of net income, and $1.2bn of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$1.4bn$2.8bn20212022202320242025Shares292m287m288m291m289m
Show the figures
Fiscal year20212022202320242025
Revenue$19.1bn$18.9bn$19.4bn$20.2bn$21.8bn
Net income$2.1bn$1.8bn$1.5bn$1.7bn$1.7bn
Stock-based pay$229.0m$233.0m$259.0m$247.0m$258.0m
Buybacks$1.8bn$500.0m$0$500.0m$1.0bn
Dividends$1.0bn$1.1bn$1.1bn$1.1bn$1.2bn
Diluted shares292m287m288m291m289m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.